WuXi Biologics (Cayman) Inc. (2269.HK)
HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
At close: 04:08PM HKT
Currency in HKD
Valuation measures4
| Market cap (intra-day) | 55.18B |
| Enterprise value | 47.95B |
| Trailing P/E | 15.89 |
| Forward P/E | 11.81 |
| PEG ratio (5-yr expected) | 0.79 |
| Price/sales (ttm) | 3.12 |
| Price/book (mrq) | 1.26 |
| Enterprise value/revenue | 2.81 |
| Enterprise value/EBITDA | 11.07 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.62 |
| 52-week change 3 | -73.70% |
| S&P500 52-week change 3 | 21.23% |
| 52-week high 3 | 52.500 |
| 52-week low 3 | 12.500 |
| 50-day moving average 3 | 16.171 |
| 200-day moving average 3 | 33.654 |
Share statistics
| Avg vol (3-month) 3 | 68.67M |
| Avg vol (10-day) 3 | 35.27M |
| Shares outstanding 5 | 4.17B |
| Implied shares outstanding 6 | 4.34B |
| Float 8 | 3.62B |
| % held by insiders 1 | 14.18% |
| % held by institutions 1 | 45.82% |
| Shares short 4 | N/A |
| Short ratio 4 | N/A |
| Short % of float 4 | N/A |
| Short % of shares outstanding 4 | N/A |
| Shares short (prior month ) 4 | N/A |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 3:1 |
| Last split date 3 | 16 Nov 2020 |
Financial highlights
Currency in CNY.Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 19.96% |
| Operating margin (ttm) | 19.09% |
Management effectiveness
| Return on assets (ttm) | 4.63% |
| Return on equity (ttm) | 8.90% |
Income statement
| Revenue (ttm) | 17.03B |
| Revenue per share (ttm) | 4.09 |
| Quarterly revenue growth (yoy) | 6.00% |
| Gross profit (ttm) | N/A |
| EBITDA | 4.65B |
| Net income avi to common (ttm) | 3.4B |
| Diluted EPS (ttm) | 0.830 |
| Quarterly earnings growth (yoy) | -39.90% |
Balance sheet
| Total cash (mrq) | 11.24B |
| Total cash per share (mrq) | 2.66 |
| Total debt (mrq) | 4.56B |
| Total debt/equity (mrq) | 10.36% |
| Current ratio (mrq) | 2.78 |
| Book value per share (mrq) | 9.55 |
Cash flow statement
| Operating cash flow (ttm) | N/A |
| Levered free cash flow (ttm) | N/A |
© 2024 Yahoo. All rights reserved.